Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer
Authors:
- Jesús Fuentes-AntrásJFJesús Fuentes-Antrás
- Ana Lucía Alcaraz-SanabriaAAAna Lucía Alcaraz-Sanabria
- Esther Cabañas MorafraileEMEsther Cabañas Morafraile
- María del Mar Noblejas-LópezMaría del Mar Noblejas-López
- Eva María Galán-MoyaEGEva María Galán-Moya
- Mariona Baliu-PiqueMBMariona Baliu-Pique
- Igor López-CadeILIgor López-Cade
- Vanesa García-BarberánVGVanesa García-Barberán
- Pedro Pérez-SeguraPPPedro Pérez-Segura
- Aránzazu ManzanoAMAránzazu Manzano
- Atanasio PandiellaAPAtanasio Pandiella
- Balázs GyőrffyBGBalázs Győrffy
Open Access
Abstract
The dysregulation of post-translational modifications (PTM) transversally impacts cancer hallmarks and constitutes an appealing vulnerability for drug development. In breast cancer there is growing preclinical evidence of the role of ubiquitin and ubiquitin-like SUMO and Nedd8 peptide conjugation to the proteome in tumorigenesis and drug resistance, particularly through their interplay with estrogen receptor signaling and DNA repair. Herein we explored genomic alterations in these processes using RNA-seq and mutation data from TCGA and METABRIC datasets, and analyzed them using a bioinformatic pipeline in search of those with prognostic and predictive capability which could qualify as subjects of drug research. Amplification of UBE2T, UBE2C, and BIRC5 conferred a worse prognosis in luminal A/B and basal-like tumors, luminal A/B tumors, and luminal A tumors, respectively. Higher UBE2T expression levels were predictive of a lower rate of pathological complete response in triple negative breast cancer patients following neoadjuvant chemotherapy, whereas UBE2C and BIRC5 expression was higher in luminal A patients with tumor relapse within 5 years of endocrine therapy or chemotherapy. The transcriptomic signatures of USP9X and USP7 gene mutations also conferred worse prognosis in luminal A, HER2-enriched, and basal-like tumors, and in luminal A tumors, respectively. In conclusion, we identified and characterized the clinical value of a group of genomic alterations in ubiquitination, SUMOylation, and neddylation enzymes, with potential for drug development in breast cancer.Keywords
Funding Information
- Instituto de Salud Carlos III (PI19/00808)
- Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R)
- Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology (2018-2.1.17-TET-KR-00001)
This publication has 53 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analysesDatabase: The Journal of Biological Databases and Curation, 2013
- It takes two to tango: Ubiquitin and SUMO in the DNA damage responseFrontiers in Genetics, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- International network of cancer genome projectsNature, 2010
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patientsBreast Cancer Research and Treatment, 2009
- Validation of UBE2C protein as a prognostic marker in node-positive breast cancerBritish Journal of Cancer, 2009
- Protein ubiquitination involving an E1–E2–E3 enzyme ubiquitin thioester cascadeNature, 1995